FORM PTO-1449				U.S. Dept. of Commerce	- 1 -	Atty Docket No.		Serial No. 10/655, 905		
Patent a				Patent and Trademark Office	ice —	47R2D1		10/	633,	107
LIST OF DISCLOSURES CITED BY APPLICANT  Applicant Garovoy et al.										
					Filing Date Group					
(Use several sheets if necessary)				•	1 1					
<b></b>	U.S. PATENT DOCUMENTS									
Examiner	Π		<u> </u>			<u> </u>	T.,			
Initials	<u> </u>	Document Number	Date	Name		Class	Subc	lass	Filing	Date
M H	* 1	5,002,869	26.03.91	Schlossman et al.			┼	ļ		
MH	* 2	5,071,964	10.12.91	Dustin et al.	٠	· <del></del>	<del>  -                                    </del>		'	
mH	* 3	6,037,454	14.03.00	Jardieu et al.						
Examiner		<del>1</del>		FOREIGN PATENT DOCUME	ENTS	<del></del>	т	<del></del> ,	Tropali	· ·
Initials		Document Number	Date	Country		Class	Subc	lass	Transla Yes	ation No
m#	* 4	8,815,518	10.11.88	AUSTRALIA			$\sqsubseteq$			
W#	* 5	2,008,368	13.06.91	CANADA			↓	~		
mH	* 6	289,949	11.11.88	EPO			<del> </del>			ĺ
mH	1	346,078	13.12.89	EPO			<del>                                     </del>			l
m4	* 8	379,904	01.08.90	EPO			<del>                                     </del>	-		ĺ
MH	* 9	387,668	19.09.90	EPO			<del>                                     </del>	- 1	.	l
MH	*10	WO 88/06592	07.09.88	PCT		-	<del>                                     </del>		.	ĺ
	*11	WO 90/10652	20.09.90	PCT			$\vdash$	<del></del>		į
mH mH	*12	WO 90/15076	13.12.90	PCT		-	<del>  _</del>	-	.	i
	*13	WO 91/16927	14.11.91	PCT.				_		l
MH	*14	WO 91/16928	14.11.91	PCT			Γ_	_		i
mat	*15	WO 91/18011	28.11.91	PCT				_		l
MI	*16	WO 94/02175	03.02.94	PCT		•	t <u>-</u>	_		
m43	*17	WO 94/04188	03.03.94	PCT				-		I
	*18	WO 98/23761	04.06.98	PCT	9			_ 1		!
				OSURES (Including Author, Title, Da						
MH	*19	Abramowicz et al.	, "Release of t	tumor necrosis factor, interle tibody in kidney transplant re	eukin-2,	and gamma-i	nterf	eron .	in serum	after
	1	(Apr 1989)								
m#	*20	Azzawi et ai., io Stable Atopic Ast	dentification of hma" Am. Rev. F	of Activated T Lymphocytes an Resp. Dis. 142:1407-1413 (1990	d Eosinop (0)	hils in Bro	nchia	I Bio	psies in	ı
mtt	*21	Bauer et al., "Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis" <u>J. Pharmacokinetics and Biopharmaceutics</u> 27(4):397-420 (1999)								
mH	•	the CD4(L3T4) and Immunology 18:107	CD11a (LFA-1) 9-1088 (1988)	Monoclonal Antibody-Facilitat Molecules in Self-Non-Self D	)iscrimina	tion" Europ	ean J	ournal	l of	
mH	*23	Campana et al., "Human leukocyte function-associated antigens on lympho-hemopoietic precursor cells" <u>European Journal of Immunology</u> 16(5):537-542 (May 1986)								
тΗ	*24	Cavazzana-Calvo et al., "A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies." British Journal of Haematology 93(1):131-138 (Apr 1996)								
mN		Cavazzana-Calvo et	t al., "Prevent	cion of bone marrow and cardia an anti-LFA-1 antibody" <u>Trans</u> r	ac graft :	rejection in	n an 1 76-15	H-2 ha 82 (Ju	plotype in 15, 1	.995)
MH	*26	Chatenoud et al., "In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids" Transplantation 49(4):697-702 (Apr 1990)								
Examine	r Mo	when Hadda	A		Date Cons				<u> </u>	
*Fxamin				at citation is in conformance with MD	-	. ,	- aitati			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

FORM PTO-1449 U.S. Dept. of Commerce			Atty Docket No.	Serial No.			
Patent and Trademark Office			P1747R2D1 10/655,90S				
1191	OF DI	SCLOSURES CITED BY APPLICANT	1 ''	Applicant			
			Garovoy et al.	Croup			
(Use several sheets if necessary)			Filing Date  05 Sep 2003	Group 1644			
		ATUED DIOM COURTS (L. L. L. A. L. T. T. D.		1644			
		OTHER DISCLOSURES (Including Author, Title, Da					
MH	*27	Chatenoud et al., "Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-q" New England J. of Medicine 320(21):1420-1421 (May 251989)					
rn H	*28	Cockcroft et al., "Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine" <u>Am. Rev. Respir. Dis.</u> 135:264-267 (1987)					
mH	*29	Collins, T., "Adhesion molecules in leukocyte emigration" <u>Science and Medicine</u> pps. 28-37 (1995)					
mH	*30	Connolly et al., "Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy" Clinical Immunology & Immunopathology 72(2):198-203 (Aug 1994)					
mH	*31	Corrigan & Kay, "CD4 T-Lymphocyte Activation in Acute Severe Asthma" Am. Rev. Respir. Dis. 141:970-977 (1990)					
mH	*32	Cosimi et al., "Use of monoclonal antibodies to T-cell subset in recipients of renal allografts" New England J. of Medicine	305(6):308-314 (Aug 6,	1981)			
mH	*33	Crescioli et al., "Theophylline inhibits early and late asthmastic subjects" <u>Ann. Allergy</u> 66:245-251 (March 1991)					
mH	*34	Curnow, R., "Clinical experience with CD64-directed immunotherapy. An overview" Cancer Immunology and Immunotherapy 45(3-4):210-215 (Nov-Dec 1997)					
mH	*35	de Fougerolles et al., "Characterization of the function of intercellular adhesion molecule (ICAM)-3 and comparison with ICAM-1 and ICAM-2 in immune responses" <u>Journal of Experimental Medicine</u> 179(2):619-629 (Feb 1, 1994)					
мH	*36	Desroches et al., "Regulation and Functional Involvement of Distinct Determinants of Leucocyte Function-Associated Antigen 1 (LFA-1) in T-Cell Activation In Vitro Scand. J. Immunol. 33:277-286 (1991)					
mH	*37	Djukanovic et al., "Effect of an Inhaled Coticosteroid on Airway Inflammation and Symptoms in Asthma"  Am. Rev. Respir, Dis. 145:669-674 (1992)					
mH	*38	Dustin and Springer, "Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells" Journal of Cell Biology 107(1):321-331 (Jul 1988)					
mH	*39	Dustin and Springer, "Role of lymphocyte adhesion receptors in transient interactions and cell locomotion" <u>Annual Review of Immunology</u> 9:27-66 (1991)					
mH	*40	Dustin et al., "Induction By IL 1 and Interferon-γ: Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecule (ICAM-1)" <u>The Journal of Immunology</u> 137(1):245-254 (July 1, 1986)					
mH	*41	Fekete et al., "Involvement of Lymphocyte Function-Associated Antigen-1 (LFA-1) But Not ICAM-1 in a Radioactive Leukocyte Cell-Mediated Immunity (LA-CMI) Assay" <u>J. Clin. Lab. Immunol.</u> 31:145-149 (1990)					
mH	*42	First et al., "The effect of indomethacin on the febrile response following OKT3 therapy"  Transplantation 53(1):91-94 (Jan 1992)					
m H	*43	Fischer et al., "Reduction of Graft Failure by a Monoclonal Antibody (Anti-LFA-1 CD11a) After HLA Nonidentical Bone Marrow Transplantation in Children with Immunodeficiencies, Osteopetrosis, and Fanconi's Anemia" <u>Blood</u> 77(2):249-256 (January 15, 1991)					
mH	*44	Fischer et al., "Role of the LFA-1 Molecule in Cellular Interactions Required For Antibody Production in Humans" The Journal of Immunology 136(9):3198-3203 (May 1, 1986)					
mH	*45	Goldman et al., "OKT3-induced cytokine release attenuation by high-dose methylprednisolone" <u>Lancet</u> 2(8666):802-803 (Sep 30, 1989)					
mH.		Goldstein et al., "A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group" New England J. of Medicine 313(6):337-342 (Aug 8, 1985)					
Examiner Mahar Haddad B116/04							
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449		1449 U.S. Dept. of Commerce	Atty Docket No.	Serial No.		
Patent and Trademark Office			P1747R2D1	10/655,905		
			Applicant			
LIST OF DISCLOSURES CITED BY APPLICANT			Garovoy et al.			
(Use several sheets if necessary)			Filing Date	Group		
			05 Sep 2003	1644		
ļ		OTHER DISCLOSURES (Including Author, Title, Date				
		Gordon et al., "Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1)	therapy delay the ons	et and diminish the		
WH	. 1 (1382)					
mH	*48	Gottlieb et al., "Psoriasis is clinically and histologically improved by treatment with a humanized anti-CD11a monoclonal antibody (hul124): results of a multicenter, multiple ascending dose study" J. Investigative Dermatology (abstract only) 112(4):647 (April 1999)				
mH	*49	He et al., "Effect of LFA-1 and ICAM-1 antibody treatment on m Opthalmol. Vis. Sci. 35:3218-3225 (1994)	urine corneal allograf	t survival" <u>Invest.</u>		
mH	*50	Hildreth et al., "A Human Lymphocyte-associated Antigen Involved in Cell-mediated Lympholysis" <u>European Journal of Immunology</u> 13:202-208 (1983)				
my	*51	Hourmant et al., "A randomized multicenter trial comparing leu monoclonal antibody with rabbit antithymocyte globulin as indutransplantations" Transplantation 62(11):1565-1570 (Dec 15, 19	ction treatment in fir	_		
MH	*52	Hourmant et al., "Administration of an Anti-CD11a Monoclonal Antibody in Recipients of Kidney				
my	*53	Isaacs et al., "Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease" Clinical & Experimental Immunology 110(2):158-166 (Nov 1997)				
m#	*54	Isobe et al., "Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1" <u>Science</u> 255(5048):1125-1127 (Feb 28, 1992)				
mH	*55	Kato et al., "Specific acceptance of fetal bowel allograft in mice after combined treatment with anti-intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 antibodies" Annals of Surgery 223(1):94-100 (Jan 1996)				
mH	*56	Krensky et al., "The Functional Significance, Distibution, and Structure of LFA-1, LFA-2, and LFA-3: Cell Surface Antigens Associated with CTL-Target Interactions" The Journal of Immunology 131(2):611-616 (August 1983)				
mH	*57	Kuypers and Roos, "Leukocyte Membrane Adhesion Proteins LFA-1, CR3 and p150,95: A Review of Functional and Regulatory Aspects" Res. Immunol. 140:461-486 (1989)				
mH	*58	Le Mauff et al., "Effect of anti-LFA1 (CD11a) monoclonal antib transplantation" <u>Transplantation</u> 52(2):291-296 (Aug 1991)	odies in acute rejecti	on in human kidney		
mH	*59	Nakakura et al., "Potent and Effective Prolongation by Anti-LFA-1 Monoclonal Antibody Monotherapy of Non-Primarily Vascularized Heart Allograft Survival in Mice Without T Cell Depletion" <u>Transplantation</u> 55(2):412-417 (February 1993)				
mH	*60	Nishihara et al., "Potent immunosuppressive effect of anti-LFA-1 monoclonal antibody on islet allograft rejection" <u>Transplantation Proc.</u> 27:372 (1995)				
mH	*61	Nishimura et al., "Lymphokine-activated cell-associated antigen involved in broad-reactive killer cell-mediated cytotoxicity" <u>Cellular Immunology</u> 94(1):122-132 (Aug 1985)				
mH	*62	Nishimura et al., "The role of lymphokine-activated cell-associated antigen. III. Inhibition of T-cell activation by monoclonal killer-blocking antibody" <a href="Mailto:Cellular Immunology">Cellular Immunology</a> 107(1):32-39 (Jun 1987)				
mH	*63	Raasveld et al., "Complement activation during OKT3 treatment: a possible explanation for respiratory side effects" <u>Kidney International</u> 43(5):1140-1149 (May 1993)				
mH	*64	Sanchez-Madrid et al., "Mapping of antigenic and functional epitopes on the α-and β-subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and MAC-1" <u>Journal of Experimental</u> Medicine 158(2):586-602 (Aug 1, 1983)				
mlt	*65	Springer et al., "The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system" <u>Annual Review of Immunology</u> 5:223-252 (1987)				
MH	<u>*</u> 66	Stoppa et al., "Anti-LFA1 Monoclonal Antibody (25.3) for Treatment of Steroid-resistant Grade III-IV 66 Acute Graft-versus-host Disease" Transplant International 4:3-7 (1991)				
Examiner Maker Haddad  Date Considered  8/16/04						
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
11 1100		ormance and not considered. Include copy or this form with next communication	io applicant.			

FORM PTO-1449			U.S. Dept. of Commerc	е	Atty Docket No.	Serial No.		
			Patent and Trademark Of	fice	P1747R2D1	10/655,905		
LIST OF DISCLOSURES CITED BY APPLICANT					Applicant			
				Garovoy et al.				
(	Use se	veral sheets if necessary)			Filing Date 05 Sep 2003	Group 16 4 リ		
		OTI	HER DISCLOSURES (Including Author, Title, I	Date. I				
Talento et al., "A single administration of LFA-1 antibody confers prolonged allograft survival"						ft survival*		
WH	*67	Transplantation 55:418-422 (1993)						
m#	*68	Tanaka et al., "Prolonged inhibition of an antigen-specific IgE response in vivo by monoclonal antibody against lymphocyte function-associated antigen-1" <u>European Journal of Immunology</u> 25:1555-1558 (1995)						
mH	*69	Taylor et al., "The expression of CD18 is increased on Trisomy 21 (Down syndrome) lymphoblastoid cells" Clinical & Experimental Immunology 71(2):324-328 (Feb 1988)						
MH	*70	infusion" <u>Transplantati</u>	et al., "Consequences of OKT3 administration via continuous infusion as compared to bolus Transplantation Proceedings 28(6):3217-3220 (Dec 1996)					
mH	*71	Van Dijken et al., "Evidence That Anti-LFA-1 in vivo Improves Engraftment and Survival After Allogeneic Bone Marrow Transplantation" Transplantation 49(5):882-886 (May 1990)						
mH	*72		Van Noort et al., "Cell Biology of Autoimmune Diseases" <u>Int Rey Cytol</u> 178:127-206 (1998)					
MH	*73	with Rejecting Renal Al	Vasconcellos et al., "Cytotoxic Lymphocyte Gene Expression in Peripheral Blood Leukocytes Correlates with Rejecting Renal Allografts" Transplantation 66:562-566 (1998)					
WH	*74	walker et al., "T Cell Subsets and Their Soluble Products Regulate Eosinophilia in Allergic and Nonallergic Asthma" <u>J. Immunol.</u> 146(6):1829-1935 (March 15, 1991)						
mH	*75	Ward et al., "Blocking of Adhesion Molecules in vivo as Anti-Inflammatory Therapy" Therapeutic Immunology 1:165-171 (1994)						
мĦ	*76	Ward et al., "Theophyllinean Immunomodulatory Role In Asthma?" Am. Rev. Respir. Dis. 147(3):518-523 (1993)						
mH	*77	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" J. of Immunology 157:4986-4995 (1996)						
mH-	*78	Woodle et al., "OKT3 escalating dose regimens provide effective therapy for renal allograft rejection" <u>Clinical Transplantation</u> 10(4):389-395 (Aug 1996)						
						*		
					·			
	****							
						·		
						•		
Examine	r 1	Naher Hadde	ad		Considered			
*Examin	er: Init	tial if reference considered, who	ether or not citation is in conformance with MP	FP 60	19: draw line through citatio	on .		
if not i	n confe	ormance and not considered.	Include copy of this form with next communicat	ion to	applicant.			